Scarica l'app Stockscreener
0.713
3.27%
0.0226
Dopo l'orario di chiusura:
.71
-0.003
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6904
Aprire:
$0.7034
Volume 24 ore:
761.22K
Relative Volume:
0.56
Capitalizzazione di mercato:
$84.83M
Reddito:
-
Utile/perdita netta:
$-93.61M
Rapporto P/E:
-0.3379
EPS:
-2.11
Flusso di cassa netto:
$-71.16M
1 W Prestazione:
+1.67%
1M Prestazione:
+1.86%
6M Prestazione:
-30.10%
1 anno Prestazione:
-38.00%
Intervallo 1D:
$0.692
$0.72
Intervallo di 1 settimana:
$0.6833
$0.75
Portata 52W:
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
Nome
Immunic Inc
Settore
Industria
Telefono
(332) 255-9818
Indirizzo
1200 AVENUE OF THE AMERICAS, NEW YORK
Confronta IMUX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.713 | 84.83M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-25 | Iniziato | William Blair | Outperform |
| 2024-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-27 | Iniziato | B. Riley Securities | Buy |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2021-04-15 | Iniziato | Aegis Capital | Buy |
| 2021-03-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-08-07 | Ripresa | ROTH Capital | Buy |
| 2020-07-20 | Iniziato | BMO Capital Markets | Outperform |
| 2020-06-05 | Iniziato | Wedbush | Outperform |
| 2020-05-11 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-25 | Iniziato | ROTH Capital | Buy |
| 2019-07-11 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Immunic Inc Borsa (IMUX) Ultime notizie
Financial Metrics Check: Immunic Inc (IMUX)’s Ratios for Trailing Twelve Months - DWinneX
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages - Defense World
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted (NASDAQ:IMUX) - Seeking Alpha
Millennium Management LLC Has $580,000 Stake in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic completes Phase 3 multiple sclerosis trial enrollmentICYMI - Proactive financial news
Immunic Therapeutics reaches major milestone with completion of ENSURE Trial Enrollment - Proactive financial news
Immunic at Jefferies Conference: Promising MS Drug Insights By Investing.com - Investing.com South Africa
Immunic at Jefferies Conference: Promising MS Drug Insights - Investing.com Australia
Small cap wrap: Midnight Sun Mining, Standard Uranium, Immunic, ReconAfrica... - Proactive Investors
Market movers: Tesla, Verint, PVH, Immunic... - Proactive financial news
Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Cap - GuruFocus
Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Capital | IMUX Stock News - GuruFocus
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials - Proactive financial news
Immunic Completes Enrollment in 2 Phase 3 Studies in Relapsing Multiple Sclerosis - MarketScreener
IMUX: Promising Results of Vidofludimus Calcium in Multiple Scle - GuruFocus
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - The Malaysian Reserve
Immunic Announces Completion of Enrollment for Both Phase 3 ENSU - GuruFocus
IMUX Completes Enrollment for Phase 3 Trials in Multiple Sclerosis | IMUX Stock News - GuruFocus
Top Executives Make Bold Moves with Major Immunic Stock Purchases! - TipRanks
Immunic Approves Equity Plan Amendment at Annual Meeting - TipRanks
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering | IMUX Stock News - GuruFocus
Immunic Announces Closing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - Longview News-Journal
Immunic raises $65M in public offering to fund clinical trials - Proactive financial news
Immunic to Participate in Investor, Scientific and Industry Conf - GuruFocus
Immunic to Participate in Investor, Scientific and Industry Conferences in June - The Malaysian Reserve
Immunic releases June conference schedule - Proactive financial news
Immunic Announces $65 Million Public Offering - TipRanks
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Eastern Progress
Immunic Inc. prices $65 million public offering By Investing.com - Investing.com South Africa
Immunic (NASDAQ:IMUX) Price Target Lowered to $10.00 at D. Boral Capital - Defense World
Immunic (IMUX) Launches $65M Public Offering, Shares Drop - GuruFocus
Immunic Tumbles After Pricing $65 Million Offering of Warrants - marketscreener.com
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Un - GuruFocus
Small cap wrap: Fineqia, Synchronoss, Santacruz Silver, Immunic... - Proactive financial news
Immunic (IMUX) Receives Target Price Adjustment from D. Boral Ca - GuruFocus
Immunic (IMUX) Receives Target Price Adjustment from D. Boral Capital | IMUX Stock News - GuruFocus
Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering - GuruFocus
Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering | IMUX Stock News - GuruFocus
Immunic (IMUX) Launches Public Offering with Warrant Options | I - GuruFocus
Immunic shares fall 12% after pricing of $65 million underwritten public offering to fund trials - Seeking Alpha
Immunic to raise up to $65M in underwritten public offering - Proactive Investors
Immunic (IMUX) Launches Public Offering with Warrant Options | IMUX Stock News - GuruFocus
Immunic Announces Pricing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com
Immunic Inc. prices $65 million public offering - Investing.com
Immunic, Inc. Announces Proposed Public Offering - Longview News-Journal
Immunic launches public offering of warrants to fund clinical trials; shares down - MSN
Immunic slides on planned equity raise - TradingView
Immunic Inc Azioni (IMUX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunic Inc Azioni (IMUX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
| Rudick Richard Alan | Director |
Nov 12 '24 |
Buy |
1.15 |
87,300 |
100,369 |
87,300 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):